Elan Outlines Spending Plan
Irish drug maker Elan said it would return $1 billion to shareholders, refinance debt and make acquisitions after the $3.25 billion sale of its stake in a multiple sclerosis drug to Biogen Idec.
Tags:
Elan Outlines Spending Plan,
Multiple Sclerosis Latest News